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Abstract
Purpose Immuno-PET is an emerging imaging tool for the
selection of high potential antibodies (mAbs) for imaging
and therapy. The positron emitter zirconium-89 (89Zr) has
attractive characteristics for immuno-PETwith intact mAbs.
Previously, we have described a multi-step procedure for
stable coupling of 89Zr to mAbs via the bifunctional chelate
(BFC) tetrafluorophenol-N-succinyldesferal (TFP-N-sucDf).
To enable widespread use of 89Zr-immuno-PET, we now
introduce the novel BFC p-isothiocyanatobenzyl-desferriox
amine B (Df-Bz-NCS) and compare its performance in 89Zr-
immuno-PET with the reference BFC TFP-N-sucDf.
Methods Three mAbs were premodified with Df-Bz-NCS
and labeled with 89Zr at different pHs to assess the reaction
kinetics and robustness of the radiolabeling. Stability of
both 89Zr-Df-Bz-NCS- and 89Zr-N-sucDf-conjugates was
evaluated in different buffers and human serum. Compar-
ative biodistribution and PET studies in tumor-bearing mice
were undertaken.
Results The selected conjugation conditions resulted in a
chelate:mAb substitution ratio of about 1.5:1. Under
optimal radiolabeling conditions (pH between 6.8–7.2),
the radiochemical yield was >85% after 60 min incubation
at room temperature, resulting in radioimmunoconjugates
with preserved integrity and immunoreactivity. The new
radioimmunoconjugate was very stable in serum for up to
7 days at 37°C, with <5% 89Zr release, and was equally
stable compared to the reference conjugate when stored in
the appropriate buffer at 4°C. In biodistribution and
imaging experiments, the novel and the reference radio-
immunoconjugates showed high and similar accumulation
in tumors in nude mice.
Conclusions The novel Df-Bz-NCS BFC allows efficient
and easy preparation of optimally performing 89Zr-labeled
mAbs, facilitating further exploration of 89Zr-immuno-PET
as an imaging tool.
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Introduction
Presently, hundreds of monoclonal antibodies (mAbs) and
mAb fragments are under clinical development because of
their excellent potential for diagnosis and systemic treat-
ment of cancer and other pathological conditions [1].
Positron emission tomography (PET) offers an attractive
imaging option to confirm and quantify selective tumor
uptake of such targeting molecules [2–4].
To enable PET imaging of intact mAbs and mAb-fragments
(immuno-PET), an appropriate positron emitter, with a half-life
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(t1/2) that is compatible with the time needed to achieve
optimal tumor-to-nontumor ratios (typically 2–4 days for
intact mAbs, and 2–4 h for mAb-fragments), has to be
securely coupled to the targeting molecule. Among others, the
following positron emitters for immuno-PET are under
investigation at the moment: gallium-68 (68 Ga; t1/2: 1.13 h),
fluorine-18 (18F; t1/2: 1.83 h), copper-64 (
64Cu; t1/2: 12.7 h),
yttrium-86 (86Y; t1/2: 14.7 h), bromine-76 (
76Br; t1/2: 16.2 h),
zirconium-89 (89Zr; t1/2: 78.4 h), and iodine-124 (
124I; t1/2:
100.3 h). Another important consideration in the choice of
a positron emitter is whether the mAb or mAb fragment
becomes internalized after binding to the target antigen. In
that case, a positron emitter is needed that residualizes in
the target cell after internalization, like 68Ga, 64Cu, 86Y,
and 89Zr, to enable imaging at optimal contrast. These
radionuclides have to be attached via chelating agents to
mAbs and mAb-fragments.
For the imaging of intact mAbs with PET, we recently
described the large-scale production of 89Zr and a strategy
for labeling mAbs with 89Zr via a multi-step synthesis using
a succinylated-derivative of desferrioxamine B (N-sucDf )
as bifunctional chelate [5]. The utility of this approach was
clearly demonstrated through high-quality 89Zr-mAb-PET
images reported in preclinical and clinical studies [6–13].
The choice of desferrioxamine B is attractive because it is
used clinically in a safe way for many years. The upcoming
commercialization of 89Zr will make this radionuclide
broadly available for research and clinical applications.
A shortcoming of the aforementioned labeling approach is
that themulti-step procedure is relatively complicated and time-
consuming, and therefore challenging with respect to Good
Manufacturing Practice (GMP) compliancy. We now introduce
a newly developed p-isothiocyanatobenzyl-derivative of des-
ferrioxamine B (Df-Bz-NCS; Macrocyclics, TX) that enables
an efficient and rapid preparation of 89Zr-labeled mAbs.
The chemical characterization of Df-Bz-NCS, its subse-
quent coupling to mAbs, and the radiolabeling of Df-Bz-
NCS conjugated mAbs with 89Zr, are described. The in
vitro stability of 89Zr-Df-Bz-NCS-mAb conjugates is
compared with the corresponding 89Zr-N-sucDf-mAb con-
jugates. In addition, comparative biodistribution and
animal-PET studies are presented.
Materials and methods
Materials, monoclonal antibodies, cell lines,
and radioactivity
All reagents were obtained from Sigma-Aldrich (St. Louis,
MO) unless otherwise stated. No special measures were
taken regarding working under strict metal-free conditions.
Deionized water (18 MΩ) was used in all reactions. Df-Bz-
NCS was obtained from Macrocyclics (cat. no. B-705).
MAb cetuximab (Erbitux; 2.0 mg/ml) directed against the
epidermal growth factor receptor (EGFR) was purchased
from Merck (Darmstadt, Germany) [14]. Selection, produc-
tion, and characterization of chimeric mAb U36 (cU36;
11.53 mg/ml) directed against CD44v6 has been described
elsewhere [15]. MAb rituximab (MabThera; 10 mg/ml)
directed against CD20 was purchased from Roche Neder-
land BV (Woerden, The Netherlands).
The human epidermoid cervical carcinoma cell line
A431 and the CD20+ B-cell lymphoma cell line Ramos
were both obtained from the American Type Culture
Collection (www.atcc.com, ATCC number: CRL-1555 and
CRL-1596, respectively). The head and neck squamous cell
carcinoma (HNSCC) cell line FaDu was obtained from
Karl-Heinz Heider (Boehringer Ingelheim, Vienna, Austria)
[16], and the HNSCC cell line UM-SCC-11B was obtained
from Dr. T.E. Carey (Ann Arbor, MI)[17].
89Zr (T1/2=78.4 h, β
+=22.6%; ~2.7 GBq/ml in 1 M oxalic
acid) was produced by BV Cyclotron VU (Amsterdam, The
Netherlands) by a (p,n) reaction on natural yttrium-89 (89Y)
and isolated with a hydroxamate column [5].
Characterization of p-Isothiocyanatobenzyl-
desferrioxamine (Df-Bz-NCS)
Synthesis of the new ligand 1-(4-isothiocyanatophenyl)-3-
[6,17-dihydroxy-7,10,18,21-tetroxo-27-[N-acetylhydroxya
mino)-6,11,17,22-tetraazaheptaeicosane)thiourea (p-isothio
cyanato-benzyl-desferrioxamine; Df-Bz-NCS) was performed
by Macrocyclics (Dallas, TX) as described before [18]. In
short, Desferrioxamine B mesylate (Df; Desferal, Novartis,
Basel) was dissolved in isopropanol/water while gently
stirring. A chloroform solution of 1,4-phenylendiisothiocya
nate and triethyl amine was then added and the reaction
progress was monitored by reverse-phase HPLC. Upon
completion, the reaction mixture was extracted with 0.1 M
HCl. The lower organic layer was concentrated in vacuo to
remove the chloroform but not the isopropanol. The
remaining organic solution was purified by reverse-phase
preparative HPLC using a water/acetonitrile gradient [De-
tector: UV/VIS at 275 nm. Column: Phenomenex Luna C18
(2) (250×50 mm, 10 μm). Sample prep: Direct injection of
the isopropanol solution. Mobile phase: 0–10 min 40/60 A/
B; 10–15 min ramp 40/60 to 90/10 A/B; 15–25 min 90/10
A/B; A=CH3CN, B=H2O. Flow rate=100 ml/min. Reten-
tion time of product was ~10 min. Desired fractions were
placed at −20°C to precipitate the product. The final product
was isolated by filtration as a white solid (41% yield).
Analytical data 1H NMR (D6-DMSO): δ 1.21 (m, −CH2,
6H), 1.38 (m, −CH2, 4H), 1.95 (s, −CH3, 3H), 2.27 (m, −CH2,
4H), 2.99 (m, CH2, 4H), 3.45 (m, CH2, 8H), 7.35 (d, 2,6-ArH,
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J=8.9 Hz, 2H), 7.75 (d, 3,5=ArH, J=8.9 Hz, 2H), 7.75
(m, N-H, 2H), 7.88 (bs, N-H, 1H), 9.59 (m, N-OH, 4H). 13C
NMR: δ 19.18 (CH3), 22.34, 22.35, 22.44, 24.88, 24.90,
24.94, 24.96, 24.98, 26.42, 26.88, 27.66, 28.78, 28.79, 28.83,
37.28, 37.92, 42.57, 42.60, 42.63, 45.67, 45.97, 121.92,
123.50, 124.98, 131.58, 138.17 (N=C=S), 169.00 (C=O),
170.20 (C=O), 170.84 (C=O), 179.02 (C=S). Elemental
analysis calculated (%) for C33H52N8O8S2: C 52.64, H 6.96,
N 14.88, S 8.52, found C 52.43, H 7.08, N 14.81, S 8.59. m/z:
(ESI+); 775 (100% [M+Na]+), (ESI-); 751 (100% [M-H]−).
Chromatographic purity: >98% Detector: UV/VIS at 225 nm.
Column: Restek Ultra IBD (100×4.6 mm, 3 μm, 100 A).
Sample prep: a 1.0 mg/ml solution prepared in DMSO.
Mobile phase: 0–10 min ramp 5/95 to 95/5 A/B; 10–15 min
95/5 A/B; A=0.1% TFA in CH3CN, B=0.1% TFA in H2O.
Preparation of 89Zr-labeled Df-Bz-NCS-mAb
cU36, cetuximab, or rituximab were premodified with Df-
Bz-NCS (Fig. 1a). In short, while gently shaking, a three-
fold molar excess of Df-Bz-NCS (in 20 μl DMSO) was
added to the mAb (2–10 mg in 1 ml 0.1 M NaHCO3 buffer,
pH 9.0), and incubated for 30 min at 37°C. Nonconjugated
chelate was removed by size exclusion chromatography
using a PD10 column (GE Healthcare Life Sciences) and
0.9% sodium chloride/gentisic acid 5 mg/ml (pH 5.0) as
eluent. Subsequently, Df-Bz-NCS-mAb was labeled with
89Zr at room temperature in a volume of 2 ml for 60 min; to
200 μl 89Zr (37–250 MBq) solution 90 μl 2 M Na2CO3
were added, after 3 min 300 μl 0.5 M HEPES buffer (pH
7.0), 710 μl Df-Bz-NCS-mAb (1–2 mg) and 700 μl 0.5 M
HEPES (pH 7.0) were added. Other pH values were
obtained by adjusting the HEPES buffer to chosen pH
values. Finally, 89Zr-Df-Bz-NCS-mAb was purified by size
exclusion chromatography (PD10 column) using 0.25 M
sodium acetate/gentisic acid 5 mg/ml buffer (pH 5.5) or
0.9% sodium chloride/gentisic acid 5 mg/ml (pH 5.0) as the
mobile phase.
Preparation of 89Zr-labeled N-sucDf-mAb
As reference to the new method for 89Zr labeling, Df was
also coupled to mAbs via the multi-step procedure as
previously described by Verel et al. [5] (Fig. 1b). In short,
the chelate Df was succinylated (N-sucDf), temporarily
filled with stable iron [Fe(III)], and coupled to the lysine
residues of the mAb (cU36 or cetuximab) by means of a
tetrafluorophenol-N-sucDf ester. After removal of Fe(III) by
transchelation to EDTA at 35°C, the premodified mAb
was purified on a PD10 column. Approximately 1 N-sucDf
moiety was coupled per mAb molecule. Subsequently, N-
sucDf-mAb was labeled with 89Zr in 0.25 M HEPES buffer
at pH 7.0; to 200 μl 89Zr (37–185 MBq) solution 90 μl 2 M
Na2CO3 were added, after 3 min 300 μl 0.5 M HEPES
buffer (pH 7.0), 710 μl N-SucDf-mAb (1–2 mg) and 700 μl
0.5 M HEPES (pH 7.0) were added. Finally, 89Zr-N-sucDf-
mAb was purified on a PD10 column using 0.9% sodium
chloride/gentisic acid 5 mg/ml (pH 5.0) or 0.25 M sodium
acetate/gentisic acid 5 mg/ml buffer (pH 5.5) as the mobile
phase.
Analyses
After each preparation of 89Zr-labeled Df-Bz-NCS-mAb or
N-sucDf-mAb, the conjugates were analyzed by instant
thin-layer chromatography (ITLC) for radiolabeling effi-
ciency and radiochemical purity, and by high-performance
liquid chromatography (HPLC) and sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
followed by phosphor imager analyses for integrity, and
by a cell-binding assay for immunoreactivity.
ITLC analyses of 89Zr-labeled N-sucDf-mAb or Df-Bz-
NCS-mAb was performed on silica gel impregnated glass
fiber sheets (Pall Corp., East Hills, NY). As the mobile
phase, 0.02 M citrate buffer (pH 5.0) was used.
HPLC monitoring of the final products was performed
on a Jasco HPLC system using a Superdex 200 10/300 GL
size exclusion column (GE Healthcare Life Sciences). As
eluent, a mixture of 0.05 M sodium phosphate and 0.15 M
sodium chloride (pH 6.8) was used at a flow rate of 0.5 ml/
min. Electrophoresis was performed on a Phastgel System
(GE Healthcare Life Sciences) using preformed 7.5% SDS-
PAGE gels under non-reducing conditions.
The immunoreactivity was determined by measuring
binding of 89Zr-cU36, 89Zr-cetuximab, or 89Zr-rituximab
(10,000 cpm/ml) to a serial dilution of 0.2% glutaraldehyde-
fixed 11B cells or 2% paraformaldehyde-fixed A431, or
Ramos cells, respectively, essentially as described by Lindmo
et al. [19].
Determination of chelate-to-mAb ratio
The Df-Bz-NCS to mAb molar ratio was determined
following a general method as described by Meares et al.
[20]. In short, conjugates were labeled according to the
aforementioned procedure with a known nanomolar excess
of zirconium oxalate solution spiked with 89Zr.
In vitro stability
For assessment of the in vitro stability of 89Zr-Df-Bz-NCS-
mAb in comparison with the reference conjugate 89Zr-N-
sucDf-mAb, two sets of experiments were performed. In a
first set, labeled mAbs were stored at 4°C (storage and
transportation conditions) and room temperature in 0.9%
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NaCl/gentisic acid 5 mg/ml or 0.25 M sodium acetate/
gentisic acid 5 mg/ml. Final activity concentration was
between 30–40 MBq/ml, specific activity was between 67–
86 MBq/mg mAb. At various time points, aliquots were
taken and analyzed by ITLC, SDS-PAGE, and HPLC.
In a second set, purified radiolabeled mAbs were added
to freshly prepared human serum (1:4 v/v dilution; sodium
azide added to 0.02%) at a final concentration of the
radiolabeled conjugates of ~1.3 nmol/ml and ~45 MBq/ml.
The samples were incubated at 37°C in a CO2-enriched
atmosphere (5% CO2). At various time points, aliquots
were taken and analyzed by TLC, SDS-PAGE, and HPLC.
Evaluation of in vivo biodistribution
For assessment of biodistribution and the in vivo stability
of the new 89Zr-Df-Bz-NCS-mAb conjugate in comparison
with the established 89Zr-N-sucDf-mAb conjugate, two sets
of experiments were performed with nude mice bearing
subcutaneously implanted human xenografts of the HNSCC
line FaDu or the vulvar tumor line A431 at two lateral
sides. In one experiment, the moderately internalizing
cU36 mAb was tested; in the other, the extensively
internalizing mAb cetuximab [21]. Female mice (HSD:
Athymic Nude-Foxn1nu, 21–31 g; Harlan) were 8 to 10
weeks old at the time of the experiments. All animal
experiments were done according to the NIH Principles of
Laboratory Animal Care and Dutch national law (“Wet op
de dierproeven”, Stb 1985, 336).
In a first experiment, mice bearing FaDu xenografts (two
groups of n=8) were injected intravenously (i.v.) with
either 89Zr-Df-Bz-NCS-cU36 (0.38±0.01 MBq) or the
reference compound 89Zr-N-sucDf-cU36 (0.38 ±
0.01 MBq). Unlabeled mAb cU36 was added to the
injection mixture to bring the total mAb dose to 100 μg
per mouse. At 72 and 144 h post-injection, four mice of
Fig. 1 Schematic representation of mAb modification with the new bifunctional chelate Df-Bz-NCS (1) and subsequent labeling with 89Zr (2) (a).
The multi-step reference procedure using desferrioxamine B as starting ligand (b)
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each group were anesthetized, bled, killed, and dissected.
After blood, tumor, and normal tissues had been
weighed, the amount of radioactivity in each sample
was measured in a gamma counter. Radioactivity uptake
was calculated as the percentage of the injected dose per
gram of tissue (%ID/g).
In a second experiment, mice bearing A431 xeno-
grafts (two groups of n=16) were injected i.v. with either
89Zr-Df-Bz-NCS-cetuximab (0.24±0.01 MBq) or the
reference compound 89Zr-N-sucDf-cetuximab (0.24±
0.01 MBq). Unlabeled cetuximab was added to the
injection mixture to bring the total mAb dose to 500 μg
per mouse. At 24, 48, 72, and 120 h post-injection, four
mice of each group were anesthetized, bled, killed, and
dissected, with further processing according to the above
procedure.
PET study
PET imaging was performed on a double-crystal-layer
HRRT PET scanner (Siemens/CTI), a dedicated small
animal and human brain scanner, as described earlier
[7, 22]. FaDu xenograft-bearing nude mice (two groups of
n=3) were anesthetized by inhalation of 2% isoflurane,
injected with either 4.12±0.04 MBq 89Zr-Df-Bz-NCS-
cU36 (~200 μg mAb) or 4.03±0.09 MBq 89Zr-N-sucDf-
cU36 (~200 μg mAb) via the retroorbital plexus, and
scanned at 72 h post-injection.
Transmission scans for attenuation and scatter correc-
tion were routinely obtained with each scan in two-
dimensional mode using a single point 137Cs source.
Three-dimensional emission scans were acquired in 64-
bit list mode during 60 min using a 400–650 keV
window. The 64-bit list mode file was first converted
into a single-frame histogram using a span of nine, and
subsequently reconstructed using a 3D ANW-OSEM
reconstruction algorithm with two iterations and 16
subsets and a matrix size of 256×256, including
corrections for normalization, decay, and dead time. For
visualization of the images, Amide’s A Medical Imaging
Data Examiner (AMIDE) was used, freely available for
download online [23]. Immediately after the PET scan the
animals were killed, and blood, tumors, major organs,
and tissues were collected, weighed, and counted in a
gamma-counter.
Statistical analyses
Differences in tissue uptake between injected conjugates
were statistically analyzed for each time point with SPSS
15.0 software using Student’s t-test for unpaired data.
Two-sided significance levels were calculated and P<0.01
was considered statistically significant.
Results
Preparation of 89Zr-Df-Bz-NCS-mAb
89Zr-Df-Bz-NCS-mAb was prepared according to the
chemical route as shown in Fig. 1a. First, Df-Bz-NCS is
coupled to the lysine groups of a mAb. Conjugation
conditions selected for this step comprised the addition of
a three-fold molar excess of Df-Bz-NCS to the mAb
solution (13–66 nmol mAb), a reaction pH of 9.0, and
incubation for 30 min at 37°C. These conditions resulted in
a reproducible chelate:mAb substitution ratio of about
1.5:1, irrespective cU36, cetuximab or rituximab was used,
as assessed by trace labeling with 89Zr in a standard
solution of Zr-oxalate.
In the next step, Df-Bz-NCS-mAbs were labeled with
89Zr in HEPES buffer (final concentration 0.25 M). After
60 min incubation at room temperature at pH 6.8–7.2, the
amount of 89Zr trans-chelated from oxalate to Df-Bz-NCS-
mAb was always more than 85% (mean, 91.9±4.6%). The
time courses of 89Zr-complexation of mAb cU36 conjugat-
ed with Df-Bz-NCS at different pHs are shown in Fig. 2.
Labeling efficiency was distinctly higher at pH 6.8 and 7.2
than at pH 6.0, 6.2, and 7.4.
Labeling of mAb cU36, cetuximab, or rituximab
modified with Df-Bz-NCS resulted in overall yields after
purification of always >80% (mean, 87.0±4.6%). The
radiochemical purity was always >95% (mean, 97.5±
0.7%; determined with ITLC and confirmed by HPLC).
The immunoreactive fraction of the different 89Zr-Df-Bz-
NCS-mAb preparations ranged from 84.1 to 96.8% at the
highest cell concentration, and was similar to those of their
131I-labeled counterparts (data not shown). HPLC and SDS-
PAGE analyses revealed optimal integrity of the different
mAbs after modification and labeling with 89Zr (data not
shown).
Evaluation of the in vitro stability
89Zr-labeled Df-Bz-NCS-mAb and N-sucDf-mAb conju-
gates were both stored in 0.9% NaCl/gentisic acid 5 mg/ml
and in 0.25 M sodium acetate/gentisic acid 5 mg/ml at 4°C
over several days to evaluate the in vitro stability. To
anticipate effects of insufficient cooling, the conjugates were
also analyzed after storage at room temperature (21°C).
Storing the 89Zr-Df-Bz-NCS-mAb conjugates in 0.25 M
sodium acetate/gentisic acid 5 mg/ml buffer (pH 5.5) at 4°C
gave the best results; only 0.9±0.4% of the initially bound
89Zr was dissociated from the mAb after 48 h, and 4.1±1.3%
after 144 h. Upon storage in the same buffer at room
temperature (21°C), 6.1±1.4% and 10.5±2.1% was dissoci-
ated after 48 h and 144 h, respectively. Also upon storage in
0.9% NaCl/gentisic acid 5 mg/ml (pH 5.0) at 4°C the
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radioimmunoconjugates remained reasonably stable, show-
ing 13.2±2.8% dissociation after 144 h. However, storage in
the same buffer at room temperature resulted in rapid release
of radioactivity from the conjugate, 48.4±5.7%. The
corresponding 89Zr-N-SucDf-mAb conjugates remained very
stable, showing less than 5% release after 144 h under all
conditions investigated.
The in vitro stability data for the 89Zr-Df-Bz-NCS-cU36 and
89Zr-N-sucDf-cU36 conjugates, when incubated in freshly
prepared human serum at 37°C, showed that loss of 89Zr from
both conjugates over a 7-day period was very small. The
percentages dissociated at day 3 were 2.3±0.1% for the Df-
Bz-NCS conjugate and 3.4±0.6% for the N-sucDf conjugate,
and at day 7 were 4.0±0.6% for the Df-Bz-NCS conjugate
and 4.7±0.5% for the N-sucDf conjugate, respectively.
Evaluation of the in vivo biodistribution
Two sets of biodistribution studies were performed. In the
first experiment, 89Zr-Df-Bz-NCS-cU36 and the reference
compound 89Zr-N-sucDf-cU36 were injected into FaDu-
bearing nude mice. At 72 and 144 h after injection, the
average %ID/g of tumor, blood, normal tissue, and
gastrointestinal contents was determined (Fig. 3). No
significant differences in the biodistribution of both
conjugates were found.
Only a minor proportion of mAb cU36 internalizes after
binding to its target antigen, therefore in the second
biodistribution study, the anti-EGFR mAb cetuximab was
chosen because of the high rate of internalization. 89Zr-Df-
Bz-NCS-cetuximab and the reference compound 89Zr-N-
sucDf-cetuximab were injected into A431-bearing nude
mice. At 24, 48, 72, and 120 h after injection, the average
%ID/g of tumor, blood, normal tissue, and gastrointestinal
contents was determined (Fig. 4). The overall biodistribu-
tion of the two radioimmunoconjugates was very similar,
showing no significant differences except for blood levels at 24
and 120 h after injection (Fig. 4; significant differences (P<
0.01) are indicated with an asterisk). The 89Zr-Df-Bz-NCS-
cetuximab tumor accumulation ranged from 15.6±4.4 %ID/g
to 23.1±7.1 %ID/g and the 89Zr-N-sucDf-cetuximab accumu-
lation from 12.3±3.2 %ID/g to 25.3±6.1 %ID/g, in the time
period between 24 and 120 h post-injection.
PET study
To exclude 89Zr uptake in tissues not evaluated in the
biodistribution experiments, a PET imaging study was
performed. Representative PET images of FaDu
xenograft-bearing nude mice at 72 h after injection with
89Zr-Df-Bz-NCS-cU36 or 89Zr-N-sucDf-cU36 are shown in
Fig. 5a or b, respectively. Immuno-PET with both radio-
immunoconjugates revealed clear delineation of the tumors
(arrows), whereas no prominent uptake of radioactivity was
observed in other tissues, except for the liver in which 89Zr
residualizes after catabolism of the conjugates.
Discussion
Immuno-PET, the tracking and quantification of mAbs and
mAb-fragments with PET in vivo, is an emerging novel
Fig. 3 Biodistribution of 89Zr-Df-Bz-NCS-cU36 (black bars) and
89Zr-N-sucDf-cU36 (white bars) in FaDu tumor-bearing nude mice at
72 h (a) and 144 h (b) after injection. Total administered mAb dose:
100 μg. Mean (%ID/g)±SD at each time point after injection (n=4
animals per time point for each conjugate)
Fig. 2 Time course of 89Zr complexation of mAb cU36 conjugated
with Df-Bz-NCS at different pH and at room temperature
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option to improve diagnostics and to guide mAb-based
therapy [2–4]. Availability of positron emitters with a
proper half-life, simple and robust radiochemistry, and
advanced animal as well as clinical PET and PET-CT
scanners, is crucial in these developments.
In the present report, we have described a method for
labeling mAbs with the long-lived positron emitter 89Zr
using the novel bifunctional chelate Df-Bz-NCS. 89Zr has
attractive characteristics for immuno-PETwith intact mAbs,
especially when these mAbs become internalized upon
Fig. 4 Biodistribution of 89Zr-Df-Bz-NCS-cetuximab (black bars)
and 89Zr-N-sucDf-cetuximab (white bars) in A431 tumor-bearing
nude mice at 24 h (a), 48 h (b), 72 h (c), and 120 h (d) after injection.
Total administered mAb dose: 500 μg. Mean (%ID/g)±SD at each
time point after injection (n=4 animals per time point for each
conjugate). Significant differences (P<0.01) in biodistribution be-
tween both radioimmunoconjugates are marked with an asterisk
Fig. 5 HRRT PET images (cor-
onal slices) of two different
FaDu xenograft-bearing nude
mice at 72 h after injection with
89Zr-Df-Bz-NCS-cU36 (a) or
with 89Zr-N-sucDf-cU36 (b).
Slices from ventral (left) to
dorsal (right). Images demon-
strate high level of radiolabeled
antibody accumulating in the
tumor (arrows point to flank
tumors) and low levels of tracer
uptake in nontarget tissues
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binding to their cellular target. Radioimmunoconjugates
produced by this method were stable in storage buffer as
well as in human serum in vitro. Biodistribution and
imaging experiments showed high and selective accumula-
tion in tumors in nude mice.
The chelate Df has frequently been used for radio-
labeling of mAbs in the past, but these conjugates have
never been evaluated clinically [24–27]. More recently,
Verel et al. [5] developed a sophisticated method for stable
coupling of 89Zr to mAbs using a succinylated-derivative of
Df, which was used as the reference method in the present
study (Fig. 1b). 89Zr-labeled mAbs prepared according to
this method have been successfully tested preclinically and
clinically [6–13]. In the past and ongoing clinical studies,
neither adverse reactions nor significant changes in blood
and urine values were observed after injection of these
conjugates. Moreover, no antibody responses directed
against the Df chelate were observed, indicating that its
immunogenicity is low [8]. These data illustrate that 89Zr-
labeled Df-mAbs can be used safely in patients. However, a
shortcoming of the aforementioned method is that the
multi-step procedure is relatively complicated and time-
consuming, and therefore challenging with respect to GMP
compliance.
Now we introduce p-isothiocyanatobenzyl-derivative of
Df (Df-Bz-NCS) that might provide an efficient and rapid
preparation of 89Zr-labeled mAbs. Bifunctional chelates
bearing isothiocyanate as the reactive group for conjugation
to mAbs or other biologicals are frequently used [28]. The
isothiocyanate group of the bifunctional chelate forms a
thiourea bond with a primary amine of the protein or mAb.
Coupling of Df-Bz-NCS to mAbs was very efficient. A
reproducible chelate:mAb substitution ratio of 1.5:1 was
obtained in a typical conjugation reaction with several
different mAbs using only a three-fold molar excess of Df-
Bz-NCS. The chelate:mAb substitution ratio was chosen to
be kept below 2 to avoid alteration of the pharmacokinetics
and immunoreactivity of the mAb [29, 30].
The rate of complexation of 89Zr into the Df-Bz-NCS
conjugate was very similar as compared to the reference N-
sucDf conjugate reported by Verel et al. [5], indicating that
the different chemical linkages (e.g., = S instead of =O
group in the side chain, which might be involved in 89Zr4+
coordination) have no influence on the complexation rate.
At the pH-optimum, almost quantitative complexation was
reached after 30 min at room temperature. The resulting
radioimmunoconjugates showed no impairment of immu-
noreactivity and integrity of the mAbs.
Radioimmunoconjugates were stored in various media to
find the optimal conditions for storage and transportation
over several days. The 89Zr-Df-Bz-NCS-mAb can best be
stored at 4°C in sodium acetate buffer in the presence of the
antioxidant gentisic acid. Under these conditions, only a
minor portion of the initially bound 89Zr was dissociated
from the mAb after 144 h. The need for protection of the
radioimmunoconjugate against radiation damage during
storage has been shown in previous studies [5, 31]. The
presence of the antioxidant ascorbic acid during storage of
high-dose 90Y— or 131I-labeled mAbs proved to be
beneficial, however, ascorbic acid cannot be used during
storage of 89Zr-labeled Df-mAbs, because this reagent
causes detachment of 89Zr from Df by reducing Zr4+ to
Zr2+ [5].
Under certain storage conditions, the new 89Zr-Df-Bz-
NCS conjugate is slightly less stable than the reference
radioimmunoconjugate, and it is important to be aware of
this. Especially the presence of Cl--ions in the storage
buffer impaired the integrity of the radioimmunoconjugates,
most likely due to the radiation-induced formation of OCl−-
ions reacting with the SH-group of the enolised thiourea-
unit. The thus formed intermediary sulphenyl chloride
bonds, and sulphonyl chloride bonds arising upon further
oxidation, are known to undergo a series of reactions,
among which are coupling reactions and cleavage of
methionyl peptide bonds. ITLC data also indicated that
most of the deterioration is not detachment of 89Zr from the
Df-chelate itself, but disruption of the Zr-Df unit.
The in vitro stability of the 89Zr-Df-Bz-NCS conjugate
and the 89Zr-N-sucDf conjugate was also compared in
freshly prepared human serum at 37°C. The stability of
both conjugates under these conditions was very compara-
ble and high, showing less than 4.7% release after a 7-day
incubation period. Serum acts as an oxidisable scavenger
and protects against directs hits to the mAb molecule,
minimizing the radiation-induced deterioration of the mAb.
Comparable in vitro stability data of 89Zr-N-sucDf con-
jugates were previously reported by our group [21].
To investigate whether the new linker used for coupling
of Df to the mAbs affects the biodistribution properties
in mice, two sets of biodistribution experiments were
performed. In the first experiment, the biodistribution of
89Zr-Df-Bz-NCS-cU36 and the reference compound
89Zr-N-sucDf-cU36 was compared in FaDu-bearing nude
mice. In this model, no significant differences in the
biodistribution between both conjugates were found.
However, only a minor proportion of mAb cU36 internalizes
after binding to its target antigen, therefore in the second
biodistribution study the anti-EGFR mAb cetuximab was
chosen because of the high rate of internalization [21]. Also
in this model, a very similar biodistribution was found.
Nevertheless, some significant differences were found, e.g.
blood levels at 24 and 120 h after injection. Overall, both
studies indicate that the different linkers used do not affect
the biodistribution properties in nude mice. Moreover, none
of the normal organs showed an adverse high uptake. The
aforementioned results were confirmed in comparative
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immuno-PET studies with both chelates. PET images did
not show accumulation of radioactivity in bone, which
would have been indicative of free 89Zr.
Conclusions
In the present study we evaluated the newly developed
bifunctional chelate Df-Bz-NCS for radiolabeling of mAbs
with 89Zr for PET-imaging. The two-step procedure allows
efficient and rapid preparation of 89Zr-labeled mAbs.
Resulting 89Zr-Df-Bz-NCS-mAb conjugates appeared opti-
mal with respect to radiochemical purity, integrity, and
immunoreactivity. Furthermore, the radioimmunoconju-
gates were stable in serum in vitro and comparative
biodistribution and imaging experiments showed high and
selective accumulation in tumors in nude mice. Special
emphasis should be given to the storage conditions. The
recent commercialization of 89Zr and the availability of
an easy-to-use radiolabeling strategy using Df-Bz-NCS
allow further exploration of 89Zr-immuno-PET as an
imaging tool for the selection of high potential candidate
mAbs for therapy as well as for the selection of patients
with the highest chance of benefit from mAb-based
therapy [2].
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